Fig. 7

Targeting TM4SF1 inhibits the growth and increases cisplatin cytotoxicity in ARID1A-depleted NSCLC cells. (A) NSCLC cells were transfected with ARID1A-targeting shRNAs and treated with anti-TM4SF1 antibody. Cell proliferation was determined by direct counting. ^*P < 0.05. (B) Colony formation assay in NSCLC cells transfected with ARID1A-targeting shRNAs and treated with anti-TM4SF1 antibody. ^*P < 0.05. (C) NSCLC cells were transfected with ARID1A-targeting shRNAs and treated with anti-TM4SF1 antibody. Cell apoptosis was measured after culturing in the presence or absence of serum for 48 h. ^*P < 0.05. (D) NSCLC cells were transfected with ARID1A-targeting shRNAs and treated with anti-TM4SF1 antibody. The cells were tested for viability after exposure to different concentrations of cisplatin for 72 h. (E) Western blot analysis of phosphorylated Akt (p-Akt) and total Akt in NSCLC cells after indicated treatments. (F) Effect of administration of anti-TM4SF1 antibody on the growth of ARID1A-depleted A549 xenograft tumors. ^*P < 0.05